Different rapid dose escalation of quetiapine in treatment of patients with schizophrenia:a multi- center parallel controlled open study

Shi Shen-xun

DOI: https://doi.org/10.3760/j.issn:1006-7884.2007.01.003

2007-01-01

Abstract:Objective The objective of this trial was to assess the safety,tolerability and efficacy in different rapid dose-escalation schedules for initiating and 4-week therapy with quetiapine treatment of patients with acute schizophrenia.Methods In this multi-center,controlled study,134 patients with 18— 65 years old meeting the Diagnostic and Statistical Manual of Mental Disorders(DSM-Ⅳ)schizophrenia criteria were involved.The patients had the Positive and Negative Syndrome Scale score of ≥60,and the Clinical Global Impression-Severity score of ≥3.They were randomly assigned to escalation schedules that would achieve a target dosage of 600 mg/d in either 4 days(200 mg/d group)or 7 days(100 mg/d group).Safety,tolerability and efficacy were assessed by interview,physical examinations and laboratory tests in days 0,7,14,21 and 28.Results The response rates at days 7 and 28 were 17% and 80% in 200 mg/d group,and 13% and 70% in 100 mg/d group,without significant difference(P0.05).The total rate of adverse events in 200 mg/d group(55%)was significantly higher than that in 100 mg/d group (33%)in first week.Somnolence and dizziness were common adverse events in both groups.Conclusion The results suggest that the efficacy of rapid escalation of 200 mg/d with quetiapine in treating acute schizophrenia is similar to the one of 100 mg/d in the first week and fourth week,with the higher rate of adverse events in 200 mg/d group in the first week.